Polivy 140 mg powder for concentrate for solution for infusion. clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN IN COMBINATION WITH RITUXIMAB AND CHP (R-CHP) VERSUS RITUXIMAB AND CHOP (R-CHOP) IN PREVIOUSLY UNTREATED PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
This study is testing a new way to treat a type of cancer called Diffuse Large B-cell Lymphoma (DLBCL). It compares a potential new drug combination with a standard one to see if it works better and is safe for people newly diagnosed with this condition.
For: Previously Untreated Diffuse large B-cell lymphoma (DLBCL)Belgium · Poland · France - AuthorisedTherapeutic exploratory (Phase II)
A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/HGBCL relapse
This study looks at new ways to decide when to start a second treatment for certain types of lymphoma, using a blood test. It aims to see if this approach is safe and effective in helping patients.
For: Diffuse large B-cell lymphomas (DLBCL · Diffuse large B-cell lymphoma) and aggressive B-cell lymphomas (HGBCL · High-grade B-cell lymphoma) originate from mature B-cells at various stages of terminal differentiationPoland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
An open-label, prospective Phase III clinical study to compare polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) with rituximab, ifosfamide, carboplatin and etoposide (R-ICE) alone as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
This study is for adults with a type of lymphoma called DLBCL that has come back or not responded to earlier treatment. It compares two treatments: a standard one (R-ICE) and a new one (Pola-R-ICE) to see which is better at stopping the cancer from growing.
For: Adult patients with relapsed or primary refractory DLBCLSpain · Austria · Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX) Versus R- GEMOX Alone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug combination, Polivy plus R-GEMOX, for adults with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this combination to R-GEMOX alone, checking for safety and how well it works.
For: Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)Italy · Germany · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase I/II Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Patients with Diffuse Large B-Cell Lymphoma following First-Line Immunochemotherapy and as Monotherapy or In Combination With Polatuzumab Vedotin in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
This study is looking at new ways to treat Diffuse Large B-Cell Lymphoma (DLBCL), a type of blood cancer. Researchers are testing a drug called mosunetuzumab, by itself or with another drug, polatuzumab vedotin. The aim is to see how well these treatments work and if they are safe.
For: Diffuse Large B-Cell Lymphoma (DLBCL)Spain · Poland